

GALAPAGOS N.V.

ISIN: BE0003818359 WKN: - Asset Class: **Stock**

Company

2024/08/15 17:38:19

Galapagos



Price
22.20
EUR

Difference  **0.36%(0.08)**



Contact Details

GALAPAGOS NV

- -

Industriepark Mechelen Noord, Generaal
de Wittelaan L11 A3
2800 Mechelen

Tel:
+32-1-534-29-00
Fax: +
Web:
<http://www.glpag.com>
E-mail: -

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,846,957,000		4,224,819,000		4,852,549,000	
Common stock capital		293,937,000		293,604,000		292,075,000
Fixed assets	510,439,000		509,532,000		340,611,000	
Equity capital of a company		2,795,566,000		2,526,026,000		2,643,362,000
Cash and cash equivalents	71,803,000		458,117,000		1,225,860,000	
Accrued liabilities		2,293,000		5,540,000		11,699,000
Other assets	-		-		-	
Current liabilities		396,179,000		522,538,000		566,474,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,165,651,000		1,685,787,000		1,983,324,000
Different income		-		-		-
Other liabilities		1,134,807,000		1,645,407,000		1,951,970,000
Total assets	4,357,396,000	4,357,396,000	4,734,351,000	4,734,351,000	5,193,160,000	5,193,160,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	1,123	1,338	1,309
Equity ratio	64.16%	53.36%	50.90%
Debt-equity ratio	55.87%	87.42%	96.46%

Others

	2023	2022	2021
Tax Expense Rate	170.90%	3.14%	6.89%

GALAPAGOS N.V.

ISIN: BE0003818359 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	239,724,000	505,280,000	484,846,000
Net income	-3,988,000	-217,991,000	-125,422,000
EBIT	-71,052,000	-235,421,000	-125,096,000
Operating income before taxes	5,625,000	-225,047,000	-134,699,000
Cash Flow	-391,205,000	-497,548,000	-503,815,000
Net interest income	76,677,000	10,374,000	-9,603,000
Research and development expenses	221,396,000	496,286,000	474,189,000
Income taxes	9,613,000	-7,056,000	-9,277,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	213,467	377,638	370,394

Board of Directors

Dan Baker	Member of Supervisory Board
Lena Elisabeth Svanberg	Member of Supervisory Board
Linda Higgins	Member of Supervisory Board
Simon Sturge	Member of Supervisory Board
Susanne Antonie Schaffert	Member of Supervisory Board
Andrew Dickinson	Member of Supervisory Board
Jérôme Contamine	Member of Supervisory Board
Peter Guenter	Member of Supervisory Board

Members of Management Board

Paul Stoffels	Chairman of Managing Board
Annelies Missotten	Member of Executive Committee
Thad Huston	Member of Executive Committee
Valeria Cnossen	Member of Executive Committee